Amanda Magrini, MD
Family Medicine · Sparks, NVNPI 1760706519
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 281 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 30.8% of the total. Reporting peaked in 2019 at $1,394 and has fallen 74.4% since, to $357 in 2025. Among family medicine clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Astellas Pharma US Inc$613
- GSK$522
- Pfizer$347
- Johnson & Johnson$243
- AstraZeneca$234
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,91298%
- Education$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 88 | $1,540 |
| Astellas Pharma US Inc | 26 | $613 |
| GSK | 30 | $522 |
| Pfizer | 30 | $347 |
| Johnson & Johnson(2 entities) | 8 | $243 |
| AstraZeneca | 12 | $234 |
| Sanofi-aventis U.S. LLC | 11 | $171 |
| Novo Nordisk | 11 | $160 |
| Amgen(2 entities) | 4 | $157 |
| Edwards Lifesciences | 2 | $121 |
| Sunovion Pharmaceuticals Inc. | 10 | $104 |
| Merck | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $68 |
| Abbott | 4 | $61 |
| Nevro Corp. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 4 | $58 |
| Corcept Therapeutics | 3 | $51 |
| Tactile Systems Technology Inc | 3 | $46 |
| Boehringer Ingelheim | 3 | $44 |
| Eisai Inc. | 3 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Medtronic | 2 | $37 |
| Lilly USA, LLC | 2 | $33 |
| Boston Scientific | 1 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Bayer | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| AMAG Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $17 |
| Axonics, Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$103
- SAPIEN 3 Ultra RESILIA$100
How this compares
$5,002 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 82 | $117,870 |
| OzempicSemaglutide | 78 | $101,630 |
| TrulicityDulaglutide | 53 | $88,903 |
| EliquisApixaban | 89 | $86,103 |
| MounjaroTirzepatide | 61 | $75,575 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $64,836 |
| XareltoRivaroxaban | 24 | $32,158 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $24,239 |
| TradjentaLinagliptin | 17 | $24,065 |
| MyrbetriqMirabegron | 35 | $23,155 |
| JanuviaSitagliptin Phosphate | 13 | $21,104 |
| FarxigaDapagliflozin Propanediol | 17 | $20,471 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $19,307 |
| LinzessLinaclotide | 28 | $17,127 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $14,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $33 | $164,479114 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $44 | $156,481117 claims |
| Novo NordiskOzempic | $160 | $101,63078 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $522 | $93,643135 claims |
| PfizerEliquis | $347 | $86,10389 claims |
| Johnson & JohnsonXarelto | $243 | $32,15824 claims |
| MerckJanuvia, Belsomra | $82 | $26,51225 claims |
| AstraZenecaFarxiga, Symbicort | $234 | $25,84933 claims |
| Astellas Pharma US IncMyrbetriq | $613 | $23,15535 claims |
| AbbVieLinzess, Synthroid | $1,540 | $21,88285 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $104 | $13,57911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.
Other family medicine in Sparks
- Ronald HicksSparks$9K
- Sangeeta WagnerSparks$8K
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Bayo Curry-WinchellReno$74K
- Warren MagnusLas Vegas$70K
- Catherine McCarthyReno$68K
- Kimberly AdamsLas Vegas$51K
- Badi EghterafiHenderson$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.